Notable
Ofirnoflast · Very Low- to Intermediate-risk Myelodysplastic Syndromes Requiring Red Blood Cell Transfusions
Primary endpoint(s) modified
Also in this update: Enrollment increased: 50 → 70 participants; Trial arms changed: 2 → 6
Halia Therapeutics, Inc.Phase 2 NCT07738510 Registry history of NCT07738510 on ClinicalTrials.gov (opens the registry)